Tasigna is a relatively new drug developed by Novartis for the treatment of leukemia. Shortly after Tasigna’s release in the United States, evidence emerged indicating that Tasigna could cause a dangerous disease called atherosclerosis (narrowing of the blood arteries to the heart). It also appears that Novartis knew or should have known about this dangerous side effect, but did not include a warning in the prescribing information.
Users of Tasigna who have suffered vascular damage from this undisclosed side effect may be entitled to compensation for their injuries. Novartis has already been sued in an increasing number of Tasigna trial and a new “class-action” MDL was created for the consolidated handling of the Tasigna business. Our practice is currently seeking new Tasigna cases from anyone who has used the drug and suffered from atherosclerosis or other type of cardiovascular injury.
What is Tasigna?
Tasigna (nilotinib) is a medicine which was developed for the treatment of a specific type of leukemia called chronic myelogenous leukemia (CML). CML is a rare type of leukemia in which cancer starts in the bone marrow and eventually enters the bloodstream. Only about 15% of leukemia cases in adult patients are classified as CML.
Tasigna is a relatively new drug in the fight against cancer. It works primarily by blocking the transmission of certain proteins that fuel the growth of leukemia cancer cells. This new drug was developed and patented by pharmaceutical giant Novartis and was first approved for use in the United States in 2007. The typical dose of Tasigna is 3000 mg twice a day.
Tasigna can cause dangerous cardiovascular problems
After Tasigna’s initial release in the United States in 2007, a steady stream of evidence began to emerge, suggesting that the drug was causing some patients dangerous and potentially fatal side effects involving the arteries and cardiovascular system. Specifically, a certain percentage of Tasigna patients have been documented to have developed atherosclerosis.
Atherosclerosis is a medical condition in which the arteries harden and narrow, disrupting blood flow to the heart. Atherosclerosis is usually a degenerative disease that develops very slowly as part of the aging process. However, patients who used Tasigna suffered from “acute atherosclerosis” in which the narrowing of the arteries occurred within months rather than decades. Acute Tasigna atherosclerosis is dangerous because it can trigger heart attacks, peripheral artery disease, or other cardiovascular injuries.
The first reports of adverse events regarding Tasigna and acute atherosclerosis led to scientific studies which confirmed that Tasigna causes acute atherosclerosis in some users. Evidence of the link between Tasigna and atherosclerosis has prompted Canadian health authorities to issue a public warning about the risks of Tasigna. In response, Novaris changed its Canadian prescribing information to include a warning about acute atherosclerosis.
Despite adding an atherosclerosis warning to the Canadian prescription label, Novartis made a conscious decision not to include an acute atherosclerosis warning on the prescription label for Tasigna in the United States. . acute atherosclerosis in some patients.
Tasigna product liability lawsuits
Novartis appears to have knowingly concealed the risk of acute atherosclerosis associated with Tasigna from doctors and patients in the United States. this. Therefore, anyone who has used the medicine and suffers from acute atherosclerosis or related cardiovascular disease may be able to hold Novartis liable for financial compensation for their injuries.
A large number of Tasigna lawsuits have already been filed against Novartis. The plaintiffs in these cases allege that Novartis was aware of the link between Tasigna and acute atherosclerosis, but intentionally hid this problem in order to maximize its profits. To date, more than 125 Tasigna lawsuits are pending in courts across the country. The bulk of these cases have been filed against Novartis in New Jersey State Court.
At the beginning of August 2021, the Tasigna lawsuits pending in federal courts were transferred to a newly created Tasigna MDL “class-action”. The more than 120 cases pending in New Jersey state courts have also been consolidated in Atlantic County under a multi-country litigation (MCL), which is the New Jersey state court equivalent of an MDL.
Hundreds and possibly thousands of more Tasigna lawsuits are expected to be filed over the next few years as more users of the drug suffer adverse health effects. Like most consolidated mass crimes involving dangerous products or drugs, Tasigna prosecutions will go through a consolidated discovery process. Upon completion of this consolidated discovery, test trials will be organized and the results of these trials are generally used to facilitate an overall settlement.
File your Tasigna lawsuit today
If you have taken Tasigna (or a generic equivalent) and have suffered any adverse cardiovascular events, you may be entitled to sue Novartis and obtain financial compensation for your injuries. Our practice is currently accepting new cases from anyone who has been prescribed Tasigna for the treatment of leukemia and who subsequently developed acute atherosclerosis or any of the following related conditions or events:
- Heart attack
- Peripheral artery discomfort
- Myocardial ischemia
If you have used Tasigna and subsequently developed any of these conditions, you may have a valid claim against Novartis.
Estimated settlement value of Tasigna lawsuits
We are still in the early stages of the Tasigna product liability litigation, so it is purely speculative to estimate what the range of potential settlement value might be for these cases. However, we can make assumptions based on the results of previous mass tort cases involving similar injuries if this litigation is successful. I don’t think these assumptions are taken out of the air, but if that’s what you are thinking, I can’t really argue with you. I agree, this is pure speculation.
The potential value of a settlement payment in a Tasigna lawsuit will largely depend on the level of harm suffered by the plaintiff. Some Tasigna plaintiffs suffered very serious injuries (even death) as a result of acute Tasigna-induced atherosclerosis. Others have more moderate injuries.
Based on previous mass crimes, I think the Tasigna cases are successful, the verdicts will be in the millions. Mass settlements are another story. I believe these cases have the following potential average settlement compensation payment value:
INJURY LEVEL ESTIMATED VALUE
LEVEL 1 $ 40,000 – $ 60,000
(acute atherosclerosis without permanent injury)
LEVEL 2 $ 80,000 – $ 150,000
(peripheral arterial disease, vascular damage,
or non-fatal heart attack)
LEVEL 3 $ 175,000 – $ 250,000
(death, stroke or leading event
Faq for Tasigna lawsuits
Can Tasigna cause cardiovascular damage?
Studies have shown that some people who use Tasigna for the treatment of leukemia can develop acute atherosclerosis, a dangerous and life-threatening cardiovascular disease.
Does Tasigna have a black box warning?
The prescription cancer drug Tasigna has a black box-shaped warning label that warns of the risk of prolongation of the QT interval – a dangerous condition involving an irregular heartbeat. However, Tasigna does not contain any warnings regarding the risk of acute atherosclerosis, which is known to be drug-related.
Is Tasigna available generically?
No. Tasigna is currently not available in a generic version and is still protected by a patent held by Novartis.